Aim immunotech provides an update on its pending phase 2a human challenge trial using its drug ampligen

Ocala, fla., sept. 20, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today provided a status update on its phase 2a human challenge trial (hct) to test the company's drug ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (hrv-16, a common cold virus) and influenza a virus (h3n2). the proposed protocol for the aim-sponsored study was submitted to the oxford research ethics committee (rec)/medicines and healthcare regulatory agency (mhra) on september 10, 2021. a meeting is scheduled to review the study on september 24, and the response is expected by mid november.
AIM Ratings Summary
AIM Quant Ranking